What are the primary concerns with using nonsteroidal anti-inflammatory drugs (NSAIDs) in late pregnancy?

The primary concerns with using nonsteroidal anti-inflammatory drugs (NSAIDs) in late pregnancy are linked to the potential for premature closure of the ductus arteriosus and an increased risk of bleeding. The ductus arteriosus is a critical fetal blood vessel that connects the pulmonary artery to the aorta, allowing blood to bypass the lungs while in utero. NSAIDs can inhibit prostaglandin synthesis, which is necessary for keeping the ductus arteriosus open. If it closes too early, it can lead to significant fetal complications, such as pulmonary hypertension and impaired blood flow.

Additionally, NSAIDs can impair platelet function, leading to an increased risk of bleeding during delivery or in the postpartum period. This heightened bleeding risk is particularly concerning in the context of both the mother’s health and the safety of the newborn.

While other options might hint at related issues, they do not represent the most significant concerns associated with NSAID use in the context of late pregnancy.